Literature DB >> 10192497

Serum C-reactive protein as a prognostic factor in patients with epithelial ovarian cancer.

J Kodama1, Y Miyagi, N Seki, K Tokumo, M Yoshinouchi, Y Kobashi, H Okuda, T Kudo.   

Abstract

OBJECTIVE: It is well known that the serum level of Interleukin-6 (IL-6) correlates with the level of C-reactive protein (CRP). The purpose of this study is to determine the significance of CRP as a prognostic factor in epithelial ovarian cancer. STUDY
DESIGN: The present study is comprised of 120 patients with epithelial ovarian cancer from 1985 to 1992. In this study, CRP levels above 50 mg/l were considered high CRP. Univariate and multivariate analyses were performed to identify clinicopathological variables associated with poor survival.
RESULTS: The serum CRP value was significantly associated with the volume of ascites (P = 0.000004). Univariate analysis showed that the FIGO stage, primary tumour diameter, size of residual tumour, histologic grade, volume of ascites and high serum level of CRP were significant prognostic factors. Cox's multivariate proportional hazard model showed that histologic grade was the most important prognostic factor (P = 0.0026). FIGO stage and volume of ascites were also independent factors for 5-year survival (P = 0.0310 and P = 0.0216, respectively). However, the serum CRP value was not an independent prognostic factor.
CONCLUSION: CRP is an adverse prognostic factor in univariate analysis, but not in multivariate analysis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10192497     DOI: 10.1016/s0301-2115(98)00227-9

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  23 in total

1.  Interleukin-6 (IL-6) and C-reactive protein (CRP) concentration prior to total nephrectomy are prognostic factors in localized renal cell carcinoma (RCC).

Authors:  Michał Hrab; Karolina Olek-Hrab; Andrzej Antczak; Zbigniew Kwias; Tomasz Milecki
Journal:  Rep Pract Oncol Radiother       Date:  2013-07-26

2.  Changes of acute-phase protein levels in the serum of lung cancer patients following radiotherapy.

Authors:  Tolia G Maria; Kouloulias E Vasileios; Pantelakos S Panagiotis; Syrigos N Kostas
Journal:  Int J Clin Exp Med       Date:  2012-11-18

3.  Prognostic value of an inflammation-based score in patients undergoing pre-operative chemotherapy followed by surgery for esophageal cancer.

Authors:  Hiroshi Miyata; Makoto Yamasaki; Yukinori Kurokawa; Shuji Takiguchi; Kiyokazu Nakajima; Yoshiyuki Fujiwara; Masaki Mori; Yuichiro Doki
Journal:  Exp Ther Med       Date:  2011-06-30       Impact factor: 2.447

4.  Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer-The GCIG Symptom Benefit Study.

Authors:  Felicia T Roncolato; Florence Joly; Rachel O'Connell; Anne Lanceley; Felix Hilpert; Luke Buizen; Aikou Okamoto; Eriko Aotani; Sandro Pignata; Paul Donnellan; Amit Oza; Elisabeth Avall-Lundqvist; Jonathan S Berek; Florian Heitz; Amanda Feeney; Dominique Berton-Rigaud; Martin R Stockler; Madeleine King; Michael Friedlander
Journal:  Oncologist       Date:  2017-06-08

5.  Pretreatment serum C-reactive protein level predicts poor prognosis in patients with hepatocellular carcinoma.

Authors:  Akiyoshi Kinoshita; Hiroshi Onoda; Keiko Takano; Nami Imai; Chisato Saeki; Nao Fushiya; Yoshinari Miyakawa; Hirokazu Nishino; Hisao Tajiri
Journal:  Med Oncol       Date:  2012-03-30       Impact factor: 3.064

6.  Differentiation between benign and malignant ovarian masses in the preoperative period using neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios.

Authors:  Melahat Yildirim; Busra Demir Cendek; Ayse Filiz Avsar
Journal:  Mol Clin Oncol       Date:  2014-12-24

7.  Pre- and post-diagnosis body mass index, weight change, and ovarian cancer mortality.

Authors:  Yang Zhou; Melinda L Irwin; Harvey A Risch
Journal:  Gynecol Oncol       Date:  2010-11-23       Impact factor: 5.482

8.  Prognostic significance of preoperative C-reactive protein elevation and thrombocytosis in patients with non-metastatic renal cell carcinoma.

Authors:  Dae Sung Cho; Se Joong Kim; Soo Hyung Lee; Hyun Soo Ahn; Young Soo Kim; Sun Il Kim
Journal:  Korean J Urol       Date:  2011-02-21

Review 9.  Impact of Body Weight and Body Composition on Ovarian Cancer Prognosis.

Authors:  Sarah A Purcell; Sarah A Elliott; Candyce H Kroenke; Michael B Sawyer; Carla M Prado
Journal:  Curr Oncol Rep       Date:  2016-02       Impact factor: 5.075

10.  Phase II biomarker trial of a multimarker diagnostic for ovarian cancer.

Authors:  Tracey Edgell; G Martin-Roussety; G Barker; D J Autelitano; D Allen; P Grant; G E Rice
Journal:  J Cancer Res Clin Oncol       Date:  2010-01-16       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.